Connection
Robert MacLaren to Fibrinolytic Agents
This is a "connection" page, showing publications Robert MacLaren has written about Fibrinolytic Agents.
|
|
Connection Strength |
|
 |
|
 |
|
0.644 |
|
|
|
-
Owen PS, Tan EC, Kiser TH, Fish DN, MacLaren R. Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). Am J Health Syst Pharm. 2010 Jan 15; 67(2):136-43.
Score: 0.289
-
MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy. 2007 Jun; 27(6):860-73.
Score: 0.241
-
Beyer JT, Schoeppler KE, Zanotti G, Weiss GM, Mueller SW, MacLaren R, Fish DN, Kiser TH. Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study. Clin Appl Thromb Hemost. 2018 Jan; 24(1):145-150.
Score: 0.115